Johnson & Johnson (NYSE:JNJ) Position Increased by Longfellow Investment Management Co. LLC

Longfellow Investment Management Co. LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,196 shares of the company’s stock after buying an additional 79 shares during the quarter. Johnson & Johnson makes up about 0.5% of Longfellow Investment Management Co. LLC’s investment portfolio, making the stock its 26th largest holding. Longfellow Investment Management Co. LLC’s holdings in Johnson & Johnson were worth $2,139,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in JNJ. China Universal Asset Management Co. Ltd. bought a new stake in Johnson & Johnson in the 1st quarter valued at $765,000. Industrial Alliance Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 22.7% in the first quarter. Industrial Alliance Investment Management Inc. now owns 8,056 shares of the company’s stock valued at $1,274,000 after buying an additional 1,488 shares during the last quarter. Sweeney & Michel LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $5,309,000. Virtus Investment Advisers Inc. boosted its position in Johnson & Johnson by 377.8% in the 1st quarter. Virtus Investment Advisers Inc. now owns 2,714 shares of the company’s stock valued at $429,000 after buying an additional 2,146 shares during the last quarter. Finally, Dynasty Wealth Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $1,213,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several analysts have weighed in on JNJ shares. Guggenheim boosted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup lifted their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $175.94.

Insider Buying and Selling

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Up 0.3 %

JNJ opened at $155.60 on Monday. The company has a 50 day moving average of $160.21 and a 200 day moving average of $156.32. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a market cap of $374.63 billion, a PE ratio of 22.46, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the company earned $2.66 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts expect that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.19%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.